Summary
Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.
Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.
Publications
Journals
Aboagye E, Brickute D, Beckley A, et al., 2021, Synthesis and evaluation of 3’-[18F]fluorothymidine-5’-squaryl as a bioisostere of 3’-[18F]fluorothymidine-5’-monophosphate, Rsc Advances: an International Journal to Further the Chemical Sciences, ISSN:2046-2069
Hu Z, Cunnea P, Zhong Z, et al., 2021, The Oxford Classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers, Clinical Cancer Research, Vol:27, ISSN:1078-0432, Pages:1570-1579
Lu H, Cunnea P, Nixon K, et al., 2021, Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer, British Journal of Cancer, ISSN:0007-0920
Natoli M, Gallon J, Lu H, et al., 2021, Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression, Journal for Immunotherapy of Cancer, Vol:9, ISSN:2051-1426
Conference
Kenny LM, Gopalakrishnan GS, Barwick TD, et al., 2021, Herpet study- PET imaging of HER2 expression in breast cancer using the novel Affibody tracer [18F]GE-226, a first in patient study, AMER ASSOC CANCER RESEARCH, ISSN:0008-5472